A Phase III Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density, Tolerability, and Safety in the Treatment of Postmenopausal Women With Osteoporosis Previously Treated With Alendronate.

Trial Profile

A Phase III Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density, Tolerability, and Safety in the Treatment of Postmenopausal Women With Osteoporosis Previously Treated With Alendronate.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2012

At a glance

  • Drugs Alendronic acid; Odanacatib
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 06 Apr 2012 Planned initiation date changed from 1 Jun 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 20 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top